[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chest-wall-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chest-wall-tumor":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,73,91,112,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100618929","chest-wall-reconstruction-cohort-100618929",false,"NCT07338006","Chest Wall Reconstruction Cohort","Comparative Outcomes of Chest Wall Reconstruction Using Twisted Steel Wires Versus Bone Cement: A Cohort Study","Inclusion Criteria:\n\n* Patients aged ≥18 years undergoing partial or full-thickness chest wall resection.\n* Defects requiring rigid or semi-rigid reconstruction involving two or more ribs or the sternum.\n\nExclusion Criteria:\n\n* Patients with small defects managed by primary closure or soft tissue-only reconstruction.\n* Patients with concurrent major intrathoracic resections (e.g., pneumonectomy) may confound postoperative respiratory assessment.\n* Recurrent disease requiring revision reconstruction.\n* Patients unwilling or unable to provide consent or comply with follow-up.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chest wall reconstruction following tumor or infection-related resections remains a challenging aspect of thoracic surgery, requiring restoration of structural stability and preservation of respiratory mechanics. While polymethyl methacrylate (PMMA) bone cement has long been used for rigid reconstruction, its limitations-including high cost, rigidity, infection risk, and interference with normal respiratory motion-pose challenges in resource-constrained settings. Twisted stainless steel wires offer a low-cost, flexible alternative that allows dynamic chest wall movement and easier adaptability in low- and middle-income countries such as Pakistan.\n\nTo compare postoperative outcomes, complications, and cost-effectiveness of chest wall reconstruction using twisted stainless steel wires versus PMMA bone cement over a two-year period (January 2025 - December 2026).\n\nThis prospective cohort study was conducted in the Department of Thoracic Surgery, Services Hospital, Lahore, a high-volume tertiary care and referral center. Patients undergoing chest wall reconstruction following resection for tumors, infections, or trauma were enrolled and divided into two groups based on the reconstruction technique used: Group A (twisted steel wires) and Group B (PMMA bone cement). Parameters assessed included postoperative pain (VAS scores), respiratory function, chest wall stability, complications (infection, wound dehiscence, prosthesis exposure), duration of hospital stay, readmission rate, and cost of reconstruction. Data were analyzed to compare clinical and functional outcomes between both cohorts.",[26,27,28],"Chest Wall Tumor","Reconstructive Surgical Procedure","Malignancy",[30,31,32,33,34,35],"Chest wall reconstruction","Bone cement","Stainless steel wire","Thoracic surgery","Postoperative pain","Functional outcomes","RECRUITING","2026-01-03",{"date":39,"type":40},"2026-01-13","ACTUAL",{"date":42,"type":40},"2021-01-01",{"date":44,"type":20},"2027-03-31",{"name":46,"class":47},"University of Health Sciences Lahore","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100596059","comparative-study-on-medical-artificial-intelligence-algorithm-assisted-and-conventional-imaging-examination-methods-100596059","NCT07040527","Comparative Study on Medical Artificial Intelligence Algorithm Assisted and Conventional Imaging Examination Methods","Comparative Study on the Clinical Efficacy of Medical Artificial Intelligence Algorithm Assisted and Conventional Imaging Examination Methods for Chest Wall Tumor Surgery","Inclusion Criteria:\n\n18-70 years old, male or female not limited Anesthesia ASA score I-II Malignant tumor of soft tissue in the chest Malignant tumors of ribs, rib cartilage, and sternum Tumors with uncertain or unknown properties of ribs, rib cartilage, and sternum Giant benign tumors of ribs, rib cartilage, and sternum The preoperative examination results indicate that the tumor has not undergone distant metastasis Willing to participate in the research and sign the informed consent form\n\nExclusion Criteria:\n\nPatients with distant metastasis detected during preoperative examination Inoperable tumor During the examination, it was discovered that the patient had another type of malignant tumor present ECOG 4 Suffering from active or chronic fungal\u002Fbacterial\u002Fviral infections History of allergy to anesthesia related drugs Heart and lung dysfunction, liver and kidney dysfunction, inability to tolerate surgery Patients with mental disorders who are unable to cooperate with treatment","70 Years",{"count":58,"type":20},100,"3 Years","OBSERVATIONAL","Chest wall tumors are one of the important diseases in thoracic surgery, and surgery remains the main method for treating this disease in clinical practice. The surgery for chest wall tumors requires extensive resection, and more importantly, precise resection. If the resection range is insufficient, it is easy to cause tumor recurrence and metastasis, which affects the patient's survival; If the resection range is too large, it will cause damage to the chest wall structure, affecting the patient's postoperative recovery and quality of life. At present, the determination of the surgical resection range mainly relies on the experience of the surgeon and the results of imaging examinations. Even if experienced surgeons still have multiple imaging examination results, there are still clinical difficulties of insufficient or excessive resection. Medical artificial intelligence is the in-depth application of artificial intelligence technology in the field of medicine. By processing and analyzing massive amounts of medical data, it can accurately locate tumors and optimize surgical plans. Therefore, it is proposed to compare the clinical effects of surgical resection of chest wall tumors using medical artificial intelligence algorithms and conventional imaging examination methods, in order to understand whether it can achieve more accurate tumor resection.",[26],"NOT_YET_RECRUITING","2025-06-19",{"date":66,"type":40},"2025-06-27",{"date":68,"type":20},"2025-07-01",{"date":70,"type":20},"2028-12-31",{"name":72,"class":47},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":90,"locationsCount":4},"100592523","comparative-study-on-different-bone-reconstruction-after-chest-wall-tumor-resection-100592523","NCT06994533","Comparative Study on Different Bone Reconstruction After Chest Wall Tumor Resection","Comparative Study on the Effect of New Reconstruction Methods and Traditional Reconstruction Methods on Bone Reconstruction After Chest Wall Tumor Resection","Inclusion Criteria:\n\n1. 18-70 years old, male or female not limited\n2. Anesthesia ASA score I-II\n3. Malignant tumor of soft tissue in the chest\n4. Malignant tumors of ribs, rib cartilage, and sternum\n5. Tumors with uncertain or unknown properties of ribs, rib cartilage, and sternum\n6. Giant benign tumors of ribs, rib cartilage, and sternum\n7. The preoperative examination results indicate that the tumor has not undergone distant metastasis\n8. Willing to participate in the research and sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients with distant metastasis detected during preoperative examination\n2. Inoperable tumor\n3. During the examination, it was discovered that the patient had another type of malignant tumor present\n4. ECOG 4\n5. Suffering from active or chronic fungal\u002Fbacterial\u002Fviral infections\n6. History of allergy to anesthesia related drugs\n7. Heart and lung dysfunction, liver and kidney dysfunction, inability to tolerate surgery\n8. Patients with mental disorders who are unable to cooperate with treatment","80 Years",{"count":19,"type":20},[23],"Chest wall tumors are one of the important diseases in thoracic surgery, and surgery is still the main treatment for this disease in clinical practice. Surgery for chest wall tumors requires extensive resection. However, the extensive chest wall defect formed after extensive resection can lead to the destruction of the integrity and stability of the chest wall, thus requiring chest wall reconstruction. The reconstruction of the chest wall after resection has always been a difficult point in chest wall tumor surgery, and the reconstruction of the chest wall bone is a key point in chest wall reconstruction. The goals of successful chest wall bone reconstruction include restoring chest wall rigidity, minimizing chest wall deformities, maintaining lung mechanics, and protecting thoracic organs. At present, traditional reconstruction methods are based on simulating and restoring the anatomical structure of the thoracic spine. For certain special areas of chest wall defects (such as posterior rib and paraspinal tumors), it is difficult to perform residual fixation; At the same time, traditional reconstruction methods suffer from insufficient stability after reconstruction, such as loosening, detachment, displacement, and even fracture. Therefore, it is necessary to design new chest wall reconstruction methods to meet clinical needs.",[26],"2025-05-20",{"date":87,"type":40},"2025-05-29",{"date":68,"type":20},{"date":70,"type":20},{"name":72,"class":47},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":110,"locationsCount":4},"100591257","artificial-intelligence-combined-with-3d-preformed-chest-wall-defection-reconstruction-system-in-chest-wall-tumor-surgery-100591257","NCT06978075","Artificial Intelligence Combined With 3D-Preformed Chest Wall Defection Reconstruction System in Chest Wall Tumor Surgery","Research on the Application of Artificial Intelligence (AI) Assisted Chest Wall Tumor Resection Combined With Personalized 3D Preformed Chest Wall Defection Reconstruction System in Chest Wall Tumor Surgery","AICW3DPCWDRS",{"count":19,"type":20},[23],"Chest wall tumors should be completely resection as much as possible while malignant chest wall tumors should be extensively resection. If not completely resection, it will recur in the short time and affect the patient's survival. At present, the surgical resection range mainly relies on preoperative imaging examination and the experience of the surgeon. It lacks precise guidance. This can easily lead to incomplete resection. In addition, the reconstruction materials required for reconstruct the excised chest wall defection are often generated in a standardized manner, lacking intraoperative adjustability. To address this clinical issue, we plan to carry out the research on the application of artificial Intelligence (AI) assisted chest wall tumor resection combined with personalized 3D preformed chest wall defection reconstruction system in chest wall tumor surgery.",[26,102],"Reconstruction Surgery",[104],"chest wall tumor resection and reconstrucion","2025-05-11",{"date":107,"type":40},"2025-05-18",{"date":68,"type":20},{"date":70,"type":20},{"name":111,"class":47},"Wu Weiming",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":48},"100591176","clinical-trial-on-the-efficacy-and-safety-of-biodegradable-3d-printed-implants-in-chest-wall-reconstruction-surgery-100591176","NCT06977022","Clinical Trial on the Efficacy and Safety of Biodegradable 3D-Printed Implants in Chest Wall Reconstruction Surgery","Clinical Trial on the Efficacy and Safety of Biodegradable 3D-Printed Implants in Chest Wall Reconstruction Surgery: A Prospective, Single-Arm Phase Il Study","Inclusion Criteria:\n\n* Patients who meet all of the following criteria are eligible to participate in the study:\n\n  1. Aged 18-70 years;\n  2. No gender restriction;\n  3. ECOG Performance Status 0-1;\n  4. Chest CT-confirmed chest wall-originating tumor;\n  5. Histologically\u002Fcytologically confirmed primary or metastatic chest wall tumor;\n  6. Anticipated intraoperative anterolateral chest wall defect diameter 5-10 cm (maximum) or costal arch reconstruction required (investigator-assessed);\n  7. Scheduled for prosthetic chest wall reconstruction;\n  8. No prior chest wall reconstruction surgery;\n  9. Willing to provide written informed consent and comply with follow-up visits and protocol requirements.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria are ineligible for this study:\n\n  1. Patients with posterior chest wall defects;\n  2. Uncontrolled underlying medical conditions or contraindications to general anesthesia;\n  3. Pregnant or lactating women;\n  4. Concurrent severe comorbidities that may interfere with study evaluations, including: Severe hepatic, cardiac, or renal diseases; Active malignancies (other than the indicated chest wall tumor); Alcohol use disorder\n  5. lnability to provide reliable symptom reporting due to:P sychiatric disorders, Severe neurosis, Non-compliance with trial requirements\n  6. Women of childbearing potential\\* and their partners unwilling to use effective contraception;\n  7. Prior history of chest wall reconstruction surgery;\n  8. Active uncontrolled bacterial, fungal, or viral infections;\n  9. Participation in other clinical trials within 3 months prior to enrollment;\n  10. Any other conditions deemedunsuitable by the investigator",{"count":120,"type":20},20,[23],"This project focuses on patients with chest wall tumors who are expected to have a maximum intraoperative anterolateral chest wall defect diameter of 5-10 cm and require chest wall reconstruction with rib implants. It aims to evaluate the efficacy and safety of biodegradable 3D-printed implants in chest wall reconstruction surgery, providing a superior reconstruction strategy for patients with tumor-induced chest wall defects.",[26],[125,126,127],"PCL Implant","Chest Wall Reconstruction","3D Printing Technology","2025-05-10",{"date":130,"type":40},"2025-05-16",{"date":132,"type":20},"2025-05",{"date":134,"type":20},"2028-05",{"name":136,"class":47},"Tang-Du Hospital",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":48},"100360279","phase-2-pembrolizumab-and-oral-metronomic-cyclophosphamide-in-patients-with-chest-wall-breast-cancer-100360279","NCT03971045","Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer","Combination of Pembrolizumab With Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer (PERICLES): A Phase II Study","PERICLES","Inclusion Criteria:\n\n* Histologically proven, PDL1 (≥1%) positive and\u002For tumor infiltrating lymphocytes (TILs) positive (≥1%), locally advanced \"chest wall\" breast cancer (with or without distant metastases), who have been treated with chemotherapy or radiation therapy may be eligible for this study. Patients with cutaneous metastases only (with or without evidence of primary tumor) are also eligible;\n* Patients must have tissue accessible for serial biopsies;\n* Expected survival of \\> 3 months;\n* Be willing and able to provide written informed consent\u002Fassent for the trial. The subject may also provide consent\u002Fassent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor;\n* Be 18 years of age on day of signing informed consent;\n* Be a female or male subject with IBC with lymphangitic spread to the chest wall. ER, PgR and HER2 status determination is required for enrollment;\n* Have provided tissue for PD-L1 biomarker analysis from a newly obtained core or excisional biopsy of a tumor lesion (mandatory) and received permission for enrollment from the Core Lab based on the adequacy of the biopsy specimen. Repeat samples may be required if adequate tissue is not provided;\n* Have measurable metastatic disease based on irRECIST criteria as determined by central radiology review. Tumor lesions situated in a previously irradiated area are considered measurable, if progression has been demonstrated in such lesions. Note: The exact same image acquisition and processing parameters should be used throughout the study;\n* Have a performance status of 0 or 1 on the ECOG Performance Scale. Assessment should be performed within 10 days of treatment initiation;\n* Female subjects of childbearing potential (Section 2.9.2) must be willing to use an adequate method of contraception as outlined in Section 2.9.2 - Contraception, for the course of the study through 120 days after the last dose of study medication;\n* Male subjects childbearing potential (Section 2.9.2) must agree to use an adequate method of contraception as outlined in Section 2.9.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject;\n* Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;\n* Patients with hormone receptor-positive and\u002For HER2-positive breast cancer would be eligible for the study only if their disease is considered refractory to hormonal or anti-HER2 agents, respectively, and no further hormonal or anti-HER2 treatment is indicated;\n* Demonstrate adequate organ function as defined in protocol, all screening labs should be performed within 10 days of treatment initiation;\n* Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required;\n* Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject;\n* Male subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment;\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment;\n* Has a known history of active TB (Bacillus Tuberculosis);\n* Hypersensitivity to pembrolizumab or any of its excipients;\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier;\n* Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Note 1: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note 2: If subject received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer;\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability;\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment;\n* Has known history of, or any evidence of active, non-infectious pneumonitis;\n* Has an active infection requiring systemic therapy;\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator;\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial;\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment;\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent;\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies);\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected);\n* Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.",{"count":146,"type":20},46,[148],"PHASE2","This is a Phase II single center, open-label, non-randomized study in patients with locally recurrent, inoperable, and\u002For metastatic inflammatory breast cancer with lymphangitic spread to the chest wall. Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle Forty-six patients will be required for the study. Key inclusion criteria are PDL1 (≥1%) positive and\u002For tumor infiltrating lymphocyte positive (≥1%) locally advanced \"chest wall\" breast cancer (with or without distant metastases), who have been treated with chemotherapy or radiation therapy may be eligible for this study. Patients with cutaneous metastases only (with or without evidence of primary tumor) are eligible for the study. Key exclusion criteria included prior anti PD1 or anti CTLA-4 or other immune pathway-targeted therapy. Patients with autoimmune diseases and\u002For receiving drugs who interfere with the immune system will not be eligible.",[151,26],"Breast Cancer",[153,154],"Pembrolizumab","Immunotherapy","2024-11-18",{"date":157,"type":40},"2024-11-19",{"date":159,"type":40},"2020-05-20",{"date":161,"type":20},"2025-03-01",{"name":163,"class":47},"European Institute of Oncology"]